Tailored Trojan horse nanocarriers for enhanced redox-responsive drug delivery

Feng, Simin; Dai, Peipei; Liu, Fang; Shang, Yaqi; Yang, Qian; Qin, Jining; Yuchi, Zhiguang; Wang, Zheng; Zhao, Yanjun

doi:10.1016/j.jconrel.2022.01.006

Cited by 17 publications

(9 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[99,100] Our recent work developed a tris(3hydroxypropyl)phosphine (THPP)-loaded hybrid nanocarrier to address this issue. [101] The reaction between THPP and disulfide is both thermodynamically and kinetically favored, which may be employed to boost the drug release. Another approach was using diselenide linkers in the carrier because the thioldiselenide reaction is kinetically very fast.…”

Section: Redox Triggermentioning

confidence: 99%

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Feng

Guo

Wang

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Nanotechnology shows the power to improve efficacy and reduce the adverse effects of anticancer agents. As a quinone‐containing compound, beta‐lapachone (LAP) is widely employed for targeted anticancer therapy under hypoxia. The principal mechanism of LAP‐mediated cytotoxicity is believed due to the continuous generation of reactive oxygen species with the aid of NAD(P)H: quinone oxidoreductase 1 (NQO1). The cancer selectivity of LAP relies on the difference between NQO1 expression in tumors and that in healthy organs. Despite this, the clinical translation of LAP faces the problem of narrow therapeutic window that is challenging for dose regimen design. Herein, the multifaceted anticancer mechanism of LAP is briefly introduced, the advance of nanocarriers for LAP delivery is reviewed, and the combinational delivery approaches to enhance LAP potency in recent years are summarized. The mechanisms by which nanosystems boost LAP efficacy, including tumor targeting, cellular uptake enhancement, controlled cargo release, enhanced Fenton or Fenton‐like reaction, and multidrug synergism, are also presented. The problems of LAP anticancer nanomedicines and the prospective solutions are discussed. The current review may help to unlock the potential of cancer‐specific LAP therapy and speed up its clinical translation.

show abstract

Section: Redox Triggermentioning

confidence: 99%

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Feng

Guo

Wang

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

show abstract

“…Curcumin is a natural polyphenol extracted from the roots of turmeric that exerts antitumor, [5,6] antibacterial, [7,8] antiinflammatory, [9] and antioxidant [10] effects. Various clinical trials have demonstrated the efficacy of curcumin for the treatment of inflammation, infectious diseases, and cancer.…”

Section: Introductionmentioning

confidence: 99%

Liposomes Co‐Delivering Curcumin and Colistin to Overcome Colistin Resistance in Bacterial Infections

Qin

Tang

Gan

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Antibiotic colistin is the last line of defense against multidrug‐resistant (MDR) Gram‐negative bacterial infections. Emergence of colistin resistance in microbes is a critical challenge. Herein, curcumin is discovered, for the first time, to reverse the resistance phenotype of colistin‐resistant bacteria via a checkerboard assay. For the co‐delivery of curcumin and colistin, negatively charged poly(ethylene glycol)‐functionalized liposomes encapsulating both drugs (Lipo‐cc) are prepared. Killing kinetics and live/dead assays confirm the antibacterial activity of Lipo‐cc against colistin‐resistant bacteria, which is more potent than that of the free curcumin and colistin combination. Mechanistical studies reveal that Lipo‐cc restores the affinity of colistin for the bacterial membrane and improves the uptake of curcumin, which leads to reduced efflux pump activity, achieving a synergistic effect of colistin and curcumin. At the effective antibacterial dose, Lipo‐cc does not exhibit any toxicity. The therapeutic efficacy of Lipo‐cc is further demonstrated in an intestinal bacterial infection model induced with colistin‐resistant Escherichia coli. Lipo‐cc reduces the bacterial burden with over 6‐log reduction and alleviated inflammation caused by infection. Importantly, unlike colistin, Lipo‐cc does not affect the homeostasis of the intestinal flora. Taken together, Lipo‐cc successfully overcame colistin resistance, indicating its potential for the treatment of colistin‐resistant bacterial infections.

show abstract

“…Apart from the difference in esterase expression due to the changes in metabolism and signaling, the level of ROS in tumor cells is higher than that in normal cells. ,− Under the continuous stimulation of such a state of oxidative stress, antioxidants (mainly referring to GSH) of tumor cells are upregulated to keep the redox balance, which is essential for maintaining the function of tumor cells. − Specifically, the concentration of GSH in tumor cells is 2–10 mM, which is significantly higher than that in normal cells (2–10 μM). , Taking advantage of this remarkable difference, many GSH-responsive SDDSs have been designed by introducing disulfide bonds as they can react with GSH and then deplete GSH to a certain extent. − …”

Section: Introductionmentioning

confidence: 99%

Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy

Shen

Zhang

Ding

et al. 2023

ACS Appl. Mater. Interfaces

View full text Add to dashboard Cite

Conventional chemotherapy usually fails to achieve its intended effect because of the poor water solubility, poor tumor selectivity, and low tumor accumulation of chemotherapy drugs. The systemic toxicity of chemotherapy agents is also a problem that cannot be ignored. It is expected that smart nano-drug delivery systems that are able to respond to tumor microenvironments will provide better therapeutic outcomes with decreased side effects of chemotherapeutics. Nano-drug delivery systems capable of breaking the redox balance can also increase the sensitivity of tumor cells to chemotherapeutics. In this study, using polymer-containing disulfide bonds, ester bonds, and d-α-tocopherol polyethylene glycol succinate (TPGS), which can amplify reactive oxygen species (ROS) in tumor cells, we have successfully prepared a smart glutathione (GSH) and esterase dual-responsive nano-drug delivery system (DTX@PAMBE-SS-TPGS NPs) with the ability to deplete GSH as well as amplify ROS and effectively release an encapsulated chemotherapy drug (DTX) in tumor cells. The potential of DTX@PAMBE-SS-TPGS NPs for enhanced antitumor effects was thoroughly evaluated using in vitro as well as in vivo experiments. Our research offers a promising strategy for maximizing the efficacy of tumor therapy.

show abstract

Tailored Trojan horse nanocarriers for enhanced redox-responsive drug delivery

Cited by 17 publications

References 48 publications

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Tailored Beta‐Lapachone Nanomedicines for Cancer‐Specific Therapy

Liposomes Co‐Delivering Curcumin and Colistin to Overcome Colistin Resistance in Bacterial Infections

Glutathione and Esterase Dual-Responsive Smart Nano-drug Delivery System Capable of Breaking the Redox Balance for Enhanced Tumor Therapy

Contact Info

Product

Resources

About